UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): July 17, 2026 |
Allurion Technologies, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware |
001-41767 |
92-2182207 |
(State or Other Jurisdiction
of Incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
|
|
|
|
|
11 Huron Drive |
|
Natick, Massachusetts |
|
01760 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: (508) 647-4000 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s) |
|
Name of each exchange on which registered
|
Common stock, par value $0.0001 per share |
|
ALUR |
|
N/A |
Warrants to purchase 0.00378787 shares of common stock, each at an exercise price of $3,037.50 per share of common stock |
|
ALUR WS |
|
N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 17, 2026, Shantanu K. Gaur, M.D. notified Allurion Technologies, Inc. (the “Company”) of his resignation as Chief Executive Officer of the Company and as a member of the Company's board of directors (the “Board”), in each case effective immediately.
Dr. Gaur's resignation was not the result of any disagreement with the Company or the Board on any matter relating to the Company's operations, policies or practices.
In connection with Dr. Gaur's resignation, the Board has not appointed an interim or permanent Chief Executive Officer. Ojas Buch, the Company's Chief Operating Officer, will oversee the Company's day-to-day operations, including certain responsibilities previously performed by Dr. Gaur. Mr. Buch’s title and compensation arrangements have not been modified in connection with these responsibilities.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
Date: |
July 23, 2026 |
By: |
/s/ Brendan M. Gibbons |
|
|
|
Name: Brendan M. Gibbons
Title:Chief Legal Officer |